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EPI Update for Friday, April 22, 2016 
Center for Acute Disease Epidemiology (CADE) 
Iowa Department of Public Health (IDPH) 
  
Items for this week’s EPI Update include: 
• Global replacement - trivalent with bivalent polio vaccine 
• Updated adult lead reference level 
• Elizabethkingia cluster in the Midwest 
• CDC Zika and pregnancy infographic – in Spanish 
• Meeting announcements and training opportunities 
  
Global replacement - trivalent with bivalent polio vaccine 
Part of the Global Polio Eradication Initiative’s strategic plan for 2013-18 called for a 
worldwide switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine 
(bOPV).This switch is part of a bigger objective that starts by introducing inactivated 
polio vaccine (IPV), and ends with withdrawing all oral polio vaccines once all wild 
polioviruses have been eradicated. 
  
Due to the success of tOPV, which contains all three poliovirus serotypes (1, 2, and 3), 
there has not been a case of wild poliovirus type 2 since 1999 and the last detected 
case of wild poliovirus type 3 was in 2012. On rare occasions in under-immunized 
populations with inadequate sanitation, the vaccine-virus excreted by immunized 
children can spread among a community long enough to mutate into a form that can 
cause paralysis. This is called circulating vaccine-derived poliovirus (cVDPV). Over 90 
percent of cVDPV polio cases are due to type 2, so switching to bivalent vaccine, which 
does not contain type 2, will greatly reduce cVDPV. 
  
Inactivated polio vaccines (IPV) were introduced in places like the U.S. in routine 
immunizations schedules. IPV protects against poliovirus types 1, 2, and 3 which will 
maintain population immunity against type 2 polio after the switch to bOPCV without 
causing cVDPV. The timeline of the eradication and endgame strategic plan calls for 
polio eradication by 2018 and withdrawal of oral polio vaccine by 2020. 
  
For more information, visit 
www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/en/. 
  
Updated adult lead reference level 
Occupational lead exposure is an important health problem and can cause adverse 
effects which range from asymptomatic changes in organ function to life-threatening 
intoxication. Lead exposure at low doses can lead to adverse cardiovascular, kidney, 
and reproductive effects, as well as cognitive problems. Current research has found 
decreased renal function associated with blood lead levels (BLLs) at 5 µg/dL 
(micrograms per deciliter) and lower, and increased risk of hypertension and essential 
tremor at BLLs below 10 µg/dL 
  
In 2015, the CDC’s National Institute for Occupational Safety and Health (NIOSH) 
designated a BLL ≥5 µg/dL as elevated (previously it was ≥10 µg/dL). This level has 
been adopted by the Iowa Adult Blood Lead Epidemiology and Surveillance (ABLES) 
program.   
  
The U.S. Occupational Safety and Health Administration (OSHA) Lead Standards 
require workers to be removed from lead exposure when BLLs are equal to or greater 
than 50 µg/dL in the construction industry or 60 µg/dL in general industry, and allow 
workers to return to work when the BLL is below 40 µg/dL. HHS recommends that BLLs 
among all adults be reduced to <10 µg/dL. Data from the National Health and Nutrition 
Examination Survey (NHANES) show the average BLL (geometric mean) of all adults in 
the United States in 2009–2010 was 1.2 µg/dL. For a visual reference, visit 
www.cdc.gov/niosh/topics/ables/pdfs/Reference%20Blood%20Levels%20for%20Adults-2015-
12-18_508.pdf. 
  
Health care providers should be aware that OSHA Lead Standards give flexibility to 
tailor special protective procedures to the needs of individual employees. The most 
current guidelines for management of lead-exposed adults should be implemented at 
the current CDC/NIOSH reference BLL of 5 µg/dL. For more information, 
visit  idph.iowa.gov/lpp/surveillance or call 800-972-2026. 
  
Elizabethkingia cluster in the Midwest 
Since January 2016, an investigation into two outbreaks caused by Elizabethkingia 
anophelis in three midwestern states has been occurring. In Wisconsin, Illinois and 
Michigan, there have been 59 confirmed cases, including 18 deaths in Wisconsin, and 
one each in Michigan and Illinois. The other outbreak occurred in 10 Illinois residents, 
six of whom have died. The strains of Elizabethkingia in these outbreaks are different. 
  
Most of the patients in these outbreaks are over the age of 65 years and have serious 
health conditions. It has not been determined if the deaths were caused primarily by the 
bacteria, the patients’ other health conditions, or a combination. 
  
Elizabethkingia anophelis is a common organism in the environment that rarely causes 
infections. Iowa has not received any reports of illness related to Elizabethkingia.  For 
more information, visit www.cdc.gov/elizabethkingia/outbreaks/index.html. 
  
CDC Zika and pregnancy infographic – in Spanish 
This week’s infographic is a Spanish version of the one provided in the Update last week. 
Although the infographic focuses on those planning to travel, it also has useful information for 
pregnant women who have returned from Zika-affected areas (e.g., symptoms and preventing 
sexual transmission). 
 
  
To access this infographic, visit 
www.cdc.gov/zika/pdfs/zika-pregnancytravel-sp.pdf. 
  
Meeting announcements and training opportunities 
None. 
  
Have a healthy and happy week! 
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